Stock Analysts

Conagra (CAG) Q2 Earnings Top Estimates, FY18 View Solid

North American food company Conagra Brands, Inc. CAG reported better-than-expected second-quarter fiscal 2018 (November 2017) results. Earnings In the fiscal second quarter, Conagra’s quarterly adjusted earnings from continuing operations came in at 55 cents, surpassing the Zacks Consensus Estimate of 52 cents. […]

Stock Analysts

Can Estee Lauder Continue to Surge Ahead of Industry in 2018?

The Cosmetics industry has been performing favorably, driven by consumers’ increased spending on personal care and beauty products. Evidently, shares of the industry gained 24.3% on a year-to-date basis, compared with the S&P 500 index’s rally of 22.8%. The Estee Lauder Companies Inc EL has emerged as one of the preferred picks for investors with its 69.3% surge this year, crushing the industry’s performance […]

Stock Analysts

Allergan/Paratek’s Acne Candidate NDA Filing Accepted by FDA

Allergan plc AGN along with partner Paratek Pharmaceuticals PRTK announced that its new drug application (NDA) for its investigational, once-daily, Seysara (sarecycline) has been accepted for review by the FDA for treatment of patients aged nine years and above with moderate to severe acne vulgaris. The company expects a response from the FDA in the second half of 2018. […]

Stock Analysts

Roche’s Perjeta Gets FDA Nod for Post Surgery Breast Cancer

Roche Holding AG ’s RHHBY announced that the FDA has approved Perjeta (pertuzumab), in combination with Herceptin and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (EBC) at high risk of recurrence. Patients should receive the adjuvant Perjeta-based regimen for one year (18 cycles). Perjeta in combination with Herceptin and docetaxel is already approved for use in patients who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer […]

Stock Analysts

GOP Passes Landmark Tax Bill: Best & Worst for Stocks

Jubilant Republicans delivered a tax bill to President Trump before Christmas, as promised. The Republican tax plan got the final approval by the House that gave Corporate America a massive permanent tax break. This in turn will encourage corporations to invest more in the United States, resulting in a rise in wages, jobs and a stronger economy. […]

Economic Data

Will Tax Cuts Keep Us at 3% GDP?

Thursday, December 21, 2017 Ahead of Thursday’s opening bell this morning, the third and final read on 3rd quarter 2017 Gross Domestic Product (GDP) was released. The good news: we keep the 3-handle for back-to-back quarters for the first time in a couple years. […]

Economic Data

Tax Cut To Boost GDP?

Ahead of Thursday’s opening bell this morning, the third and final read on 3rd quarter 2017 Gross Domestic Product (GDP) was released. The good news: we keep the 3-handle for back-to-back quarters for the first time in a couple years. The bad news (and it’s not that bad): the 3.2% tally is a tenth less than the previous read of 3.3%. […]

Technicals

Why Big 5 Sporting Goods (BGFV) Stock Might be a Great Pick

One stock that might be an intriguing choice for investors right now is Big 5 Sporting Goods Corporation BGFV . This is because this security in the Retail-Wholesale space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. […]

Technicals

Why the Earnings Streak Will Continue for Curtiss-Wright (CW)

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Curtiss-Wright Corporation CW , a firm in the Aerospace – Defense Equipment industry, which could be a great candidate for another beat. This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports […]